New drug combo tested for tough-to-treat cancers
NCT ID NCT04670679
First seen Mar 28, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This early-phase study tests an experimental drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 90 participants will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89014, United States
-
Linear Clinical Research
Perth, Western Australia, Australia
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
-
Sarah Cannon Research Institute (Florida Cancer Specialists)
Sarasota, Florida, 34232, United States
-
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.